Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9954434 | Biochimica et Biophysica Acta (BBA) - Reviews on Cancer | 2018 | 68 Pages |
Abstract
In this review, the most promising candidates from the new generation of PI3K-pathway inhibitors is explored, presenting evidence from preclinical and early clinical research, as well as ongoing trials utilising these drugs in breast cancer cohorts. The problems hindering the development of drugs targeting the PI3K pathway are examined, which have created problems for their use as monotherapies. PI3K pathway inhibitor combinations therefore remains a dynamic research area, and their role in combination with immunotherapies and epigenetic therapies is also inspected.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Michael Mc Kenna, Sarah McGarrigle, Graham P. Pidgeon,